Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449813
Status:
TERMINATED
Last Update Posted:
2012-05-07
First Post:
2007-03-02
Brief Title:
The CONQUEST-Study Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms BY1023NL511
Sponsor:
Takeda
Organization:
Takeda
Study Overview
Official Title:
The CONQUEST-Study Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms
Status:
TERMINATED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Inclusion-rate does not seem feasible anymore to obtain te required number of patients before the end of the trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to compare two different endpoint measures heartburn as assessed by the physicians versus gastroesophageal reflux disease GERD-related symptoms as assessed by the patient using the ReQuest questionnaire The assessment is made in GERD-patients treated with a daily dose of 40 mg oral pantoprazole over an 8-week period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None